Company goal is not to demonstrate one drug or another as more effective, but to define models which use past data and intended dosing to predict future values. This capability is essential for deciding which intended drug choice and dose is best for the patient.

Advances in computability allow for the progression from asking what is safe and effective for a group to detailed prediction of drug impact on the individual patient. This drives a revolution in personalized medicine and the drug approval process. The company is well positioned to be a leader as part of this seismic change.

Company has several years of Dana-Farber MyChart and other health institution data which includes the usual blood tests, PET scans, etc. Dataset is further enhanced by detailed dosing history coming from patient daily logs. There are tens of thousands of images tracking tumor wounds and other features. Camera image data can show drug driven changes on the granularity of a few days -- faster than possible from more invasive image scanning results. Faster and more tumor site specific than possible from blood tests.

It is expected that inclusion of 10x Genomics data will enhance several aspects of site dependent disease progression. Because CDK4/6 inhibitors work by putting cancer cells into a suspended state, 10x samples can function like tree cores allowing analysis of a cancer genomics evolutionary history.

Existing tools provide easy and complete access (with permission) to patient MyChart data. Blood lab test results are available in a per institution csv file, facilitating analysis and visualization with Python libraries: NumPy, pandas, matplotlib, Seaborn, etc.

Cambridge Precision Dosing Inc.

Org chart

Teams

Offices

Cambridge Precision Dosing Inc.

Org chart

Teams

Offices

Related companies